Pound falls to a three-week low against the euro as markets show concern over the risk of expanding UK fiscal deficit
智通财经2026/07/27 15:31- The British pound slid to a three-week low against the euro on Monday, as a series of fiscal measures announced by the new government raised concerns about the sustainability of public finances, prompting investors to adopt a noticeably more cautious stance.
- The latest stimulus package includes measures such as reducing taxes related to electricity bills, lowering business taxes for pubs and entertainment venues, and setting a cap on bus ticket prices. These initiatives aim to alleviate cost-of-living pressures on households and boost consumer spending.
- Institutional analysis points out that these tax cuts generally lack clearly defined funding sources, increasing the potential risk of further future tax hikes or additional debt issuance. This uncertainty regarding the path of fiscal expansion is unsettling market participants.
- At the exchange rate level, the euro once climbed to around 0.8559 against the pound, while the pound also weakened slightly against the US dollar, trading near the 1.3380 mark. This reflects a temporary contraction in external investors’ risk appetite for UK assets. The future trend of the pound will depend on the market’s reassessment of the credibility of the new government's fiscal framework and further clarification of central bank policy direction.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%
On Monday, storage chip concept stocks generally rose, with SanDisk (SNDK.US) up by 6%.
AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds
On August 17, AstraZeneca (AZN.US) and Daiichi Sankyo jointly announced that the Phase III DESTINY-Lung04 study of Enhertu (trastuzumab deruxtecan) as a monotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has achieved highly positive results.
Nvidia invests $1.5 billion in SB Energy to support Ohio AI data center campus
Crypto prices
More
